Results 61 to 70 of about 2,874 (159)

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-lactamases, in particular, serine carbapenemases, and is currently approved in combination with meropenem as Vabomere for the treatment of complicated urinary tract infections, including pyelonephritis.
David C. Griffith, Mojgan Sabet, Ziad Tarazi, Olga Lomovskaya, Michael N. Dudley   +4 more
openaire   +2 more sources

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Angewandte Chemie International Edition, Volume 64, Issue 10, March 3, 2025.
This article provides an overview over antibacterial drugs investigated in the past three decades. Aspects of the compound's origins, their cellular targets, the antibacterial spectrum and proof‐of‐concept in animal studies are covered and current trends are highlighted.
Roderich D. Süssmuth, Marcel Kulike‐Koczula, Peng Gao, Simone Kosol   +3 more
wiley   +1 more source

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source

Infections Management in the Lung Transplant Setting in Italy: A Web‐Survey

Transplant Infectious Disease, Volume 27, Issue 2, March/April 2025.
A web survey has revealed significant variation in infection management practices across Italian lung transplant centers. These differences encompass key aspects of infection prevention and control, including antibiotic protocols and cytomegalovirus prophylaxis, underscoring a lack of consistency in fundamental strategies.
Andrea Lombardi, Paolo Grossi, Malgorzata Mikulska, Maddalena Giannella, Renato Pascale, Serena Marinello, Francesca Montagnani, Elena Seminari, Silvia Corcione, Alessandra Bandera, Alessandro Bertani, Alessandra Mularoni, for the Infection Prevention and Treatment Working Group of the LUNG‐SITO study group   +12 more
wiley   +1 more source

α‐Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML

ChemMedChem, Volume 20, Issue 1, January 2, 2025.
Boronic acids represent an intriguing and unexplored class of compounds in the context of acute myeloid leukemia (AML), and they are only scantly reported as inhibitors of protein kinases. The screening of an in‐house library of boronic compounds identified α‐triazolylboronic acids as a novel chemotype for targeting FLT3 in AML. Selected compounds show
Maria Luisa Introvigne, Lorenza Destro, Luca Mologni, Valentina Crippa, Paolo Zardi, Francesco Fini, Fabio Prati, Emilia Caselli, Alfonso Zambon   +8 more
wiley   +1 more source

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection. [PDF]

J Pediatr Pharmacol Ther
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Sano U, Meyers R, Hasan U, Smoke S.
europepmc   +2 more sources

Cefiderocol‐Resistant Elizabethkingia anophelis Bacteremia Following WATCHMAN Implantation: A Case Report and Review of the Literature

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Elizabethkingia anophelis is an emerging pathogen associated with nosocomial and community outbreaks. Treatment of infection caused by E. anophelis is not well‐defined given its extensive drug resistance profile, and infection carries a poor prognosis. E.
Anna DeFrank, Michael Bosco, Sigridh Muñoz Gómez, Amit Dhaliwal, Priya Gusain   +4 more
wiley   +1 more source

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2485-2489, September 2025.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

A Case of Nocardia kroppenstedtii Infection Successfully Treated With a Multidisciplinary Approach

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Nocardia species constitute a diverse group of microorganisms classified as aerobic actinomyces. Among these species, many have been implicated as causative agents of severe human infections, particularly in immunocompromised patients, affecting lungs, skin, and nervous system.
Francesco Foglia, Annalisa Ambrosino, Giuseppe Greco, Annalisa Chianese, Carla Zannella, Francesca Cinone, Alfonso Reginelli, Diego Sandro Giordano, Giovanni Tortorella, Maria Teresa Laieta, Anna De Filippis, Massimiliano Galdiero, Rita Greco, Emiliana Finamore, Rajib Chowdhury   +14 more
wiley   +1 more source